**4th International Research Conference on Alpha-1 Antitrypsin**
**Beyond the Folding: Disease Progression and Therapeutic Options**

**Scientific Program**

**Wednesday, April 3, 2019**

12:30pm-02:30pm  Lunch

**Welcome**

02:30pm – 02:35pm  Adam Wanner (Alpha-1 Foundation, USA)

**Chairman’s Remarks**

02:35pm – 02:45pm  Rob Stockley (University Hospitals Birmingham, United Kingdom)

**Session 1: The Lung**

02:45pm – 03:05pm  Brian Hobbs (Brigham and Women's Hospital, USA)

*Why is disease penetration so variable? Role of Genetic modifiers*

03:05pm – 03:25pm  Discussion

03:25pm – 03:45pm  Alice Turner (University of Birmingham, United Kingdom)

*Why is disease penetration so variable? Environmental factors*

03:45pm – 04:05pm  Discussion

04:05pm – 04:25pm  Charlie Strange (Medical University of South Carolina, USA)

*Should all patients with established COPD be treated with augmentation therapy?*

04:25pm – 04:45pm  Discussion

04:45pm – 05:05pm  Rick Santorum, Special Guest Speaker

05:05pm – 05:25pm  Omar Usmani (Imperial College London, United Kingdom)

*Feasibility of aerosol alpha-1 antitrypsin as an alternative approach*

05:25pm – 05:45pm  Discussion

05:45pm – 06:05pm  Liz Sapey (University of Birmingham, United Kingdom)

*Neutrophil modulation*

06:05pm – 06:25pm  Discussion
Thursday, April 4, 2019

Session 1: The Lung

08:00am – 08:20am  Sabina Janciauskiene (Hannover Medical School, Germany)  
*The beneficial effect of Antioxidants*

08:20am – 08:40am  Discussion

08:40am – 09:00am  Gerry McElvaney (Royal College of Surgeons in Ireland, Ireland)  
*Anti-cytokines as a strategy*

09:00am – 09:20am  Discussion

09:20am – 09:40am  Rob Stockley (University Hospitals Birmingham, United Kingdom)  
*Anti-proteases. Which one/s?*

09:40am – 10:00am  Discussion

10:00am – 10:20am  Coffee Break

10:20am – 10:40am  Frank Sciurba (University of Pittsburgh School of Medicine, USA)  
*Surgical and bronchoscopic interventions*

10:40am – 11:00am  Discussion

Session 2: The Liver

11:00am – 11:20am  Graeme Alexander (University College London, United Kingdom)  
*The pathophysiology and monitoring of Cirrhosis*

11:20am – 11:40am  Discussion

11:40am – 12:00pm  Pavel Strnad (University Hospital Aachen, Germany)  
*Fibroscans in AATD as a monitoring tool*

12:00pm – 12:20pm  Discussion

12:20pm – 2:00pm  Lunch

02:00pm – 02:20pm  Rick Sifers (Baylor College of Medicine, USA)  
*Liver regrowth*

02:20pm – 02:40pm  Discussion

02:40pm – 03:00pm  Marion Bouchecareilh (INSERM U1053 BaRITon, France)  
*Why do some patients do badly?*
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>03:00pm – 03:20pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>03:20pm – 03:40pm</td>
<td>Pro: Jeffrey Teckman (Saint Louis University, USA) Con: William Balch (Scripps Research, USA)</td>
<td><em>Gene silencing is more appropriate than small molecules</em></td>
</tr>
<tr>
<td>03:40pm – 04:00pm</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**Closing Remarks**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>04:00pm – 04:05pm</td>
<td>Adam Wanner (Alpha-1 Foundation, USA)</td>
<td></td>
</tr>
</tbody>
</table>